recent publications

• academic article

  • Roffi, M., Moliterno, D. J., Meier, B., Powers, E. R., Grines, C. L., DiBattiste, P. M., Herrmann, H. C., Bertrand, M., Harris, K. E., Demopoulos, L. A., Topol, E. J., TARGET Investigators Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up Circulation  2002 105:2730-2736  DOI:10.1161/01.cir.0000018123.02672.c7  PMID:12057986
  • Stone, G. W., Moliterno, D. J., Bertrand, M., Neumann, F. J., Herrmann, H. C., Powers, E. R., Grines, C. L., Moses, J. W., Cohen, D. J., Cohen, E. A., Cohen, M., Wolski, K., et al. Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial Circulation  2002 105:2347-2354  DOI:10.1161/01.cir.0000017635.82128.8c  PMID:12021219
  • Topol, E. J., Moliterno, D. J., Herrmann, H. C., Powers, E. R., Grines, C. L., Cohen, D. J., Cohen, E. A., Bertrand, M., Neumann, F. J., Stone, G. W., DiBattiste, P. M., Demopoulos, L., et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization New England Journal of Medicine  2001 344:1888-1894  DOI:10.1056/nejm200106213442502  PMID:11419425